CL2014000590A1 - Anticuerpo o fragmento de union a antigeno del mismo que se une a pcsk9 humana; composicion farmaceutica que lo comprende; y su uso para tratar hiperlipidemia o hipercolesterolemia. - Google Patents
Anticuerpo o fragmento de union a antigeno del mismo que se une a pcsk9 humana; composicion farmaceutica que lo comprende; y su uso para tratar hiperlipidemia o hipercolesterolemia.Info
- Publication number
- CL2014000590A1 CL2014000590A1 CL2014000590A CL2014000590A CL2014000590A1 CL 2014000590 A1 CL2014000590 A1 CL 2014000590A1 CL 2014000590 A CL2014000590 A CL 2014000590A CL 2014000590 A CL2014000590 A CL 2014000590A CL 2014000590 A1 CL2014000590 A1 CL 2014000590A1
- Authority
- CL
- Chile
- Prior art keywords
- hypercholesterolemia
- binds
- antibody
- pharmaceutical composition
- antigen binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161535625P | 2011-09-16 | 2011-09-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2014000590A1 true CL2014000590A1 (es) | 2014-10-17 |
Family
ID=46881177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2014000590A CL2014000590A1 (es) | 2011-09-16 | 2014-03-12 | Anticuerpo o fragmento de union a antigeno del mismo que se une a pcsk9 humana; composicion farmaceutica que lo comprende; y su uso para tratar hiperlipidemia o hipercolesterolemia. |
Country Status (28)
Country | Link |
---|---|
US (1) | US8530414B2 (es) |
EP (1) | EP2756003A1 (es) |
JP (1) | JP6013487B2 (es) |
KR (1) | KR101607783B1 (es) |
CN (1) | CN103781802B (es) |
AP (1) | AP2014007499A0 (es) |
AR (1) | AR087715A1 (es) |
AU (1) | AU2012308786B2 (es) |
BR (1) | BR112014005799A2 (es) |
CA (1) | CA2845706C (es) |
CL (1) | CL2014000590A1 (es) |
CO (1) | CO6910164A2 (es) |
CR (1) | CR20140087A (es) |
DO (1) | DOP2014000041A (es) |
EA (1) | EA024430B1 (es) |
EC (1) | ECSP14013242A (es) |
GT (1) | GT201400049A (es) |
IL (1) | IL231282A0 (es) |
MA (1) | MA35433B1 (es) |
MX (1) | MX347475B (es) |
MY (1) | MY168961A (es) |
PE (1) | PE20141147A1 (es) |
SG (1) | SG2014014187A (es) |
TN (1) | TN2014000094A1 (es) |
TW (1) | TWI586687B (es) |
UA (1) | UA114604C2 (es) |
WO (1) | WO2013039958A1 (es) |
ZA (1) | ZA201401267B (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11904017B2 (en) | 2015-08-18 | 2024-02-20 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
SG192118A1 (en) | 2011-01-28 | 2013-09-30 | Sanofi Sa | Pharmaceutical compositions comprising human antibodies to pcsk9 |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
MX363642B (es) | 2011-09-16 | 2019-03-28 | Regeneron Pharma | Metodos para reducir los niveles de lipoproteina (a) administrando un inhibidor de proproteina convertasa subtilisina kexina-9 (pcsk9). |
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
US10058630B2 (en) * | 2012-10-22 | 2018-08-28 | Concievalve, Llc | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
EP2810955A1 (en) | 2013-06-07 | 2014-12-10 | Sanofi | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
EP2862877A1 (en) | 2013-10-18 | 2015-04-22 | Sanofi | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
EP3004171B1 (en) | 2013-06-07 | 2021-10-13 | Regeneron Pharmaceuticals, Inc. | Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9 |
EP3013422A1 (en) * | 2013-06-28 | 2016-05-04 | Amgen Inc. | Methods for treating homozygous familial hypercholesterolemia |
EA201690889A1 (ru) | 2013-11-12 | 2016-11-30 | Санофи Байотекнолоджи | Режимы дозирования для применения ингибиторов pcsk9 |
US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
US9051378B1 (en) | 2014-07-15 | 2015-06-09 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US9023359B1 (en) | 2014-07-15 | 2015-05-05 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
US9045548B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment |
US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
DE202014010499U1 (de) | 2013-12-17 | 2015-10-20 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
CN105085684B (zh) * | 2014-05-14 | 2020-04-17 | 上海亨臻实业有限公司 | Pcsk9靶向重组疫苗设计及其应用 |
DE202015009007U1 (de) | 2014-07-15 | 2016-08-19 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
WO2016008899A1 (en) | 2014-07-15 | 2016-01-21 | Kymab Limited | Targeting human pcsk9 for cholesterol treatment |
US9150660B1 (en) | 2014-07-15 | 2015-10-06 | Kymab Limited | Precision Medicine by targeting human NAV1.8 variants for treatment of pain |
EP3332790A1 (en) | 2014-07-15 | 2018-06-13 | Kymab Limited | Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations |
US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
PL3169353T3 (pl) | 2014-07-16 | 2020-06-01 | Sanofi Biotechnology | SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH) |
WO2016023916A1 (en) | 2014-08-12 | 2016-02-18 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
WO2016071701A1 (en) | 2014-11-07 | 2016-05-12 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
KR20170123345A (ko) * | 2015-03-20 | 2017-11-07 | 오르후스 우니베르시테트 | 지질단백질 대사 장애의 치료를 위한 pcsk9의 억제제 |
US11052175B2 (en) | 2015-08-19 | 2021-07-06 | Musculoskeletal Transplant Foundation | Cartilage-derived implants and methods of making and using same |
CN106810609A (zh) * | 2015-11-27 | 2017-06-09 | 苏州君盟生物医药科技有限公司 | 抗pcsk9抗体及其应用 |
RU2739208C2 (ru) * | 2015-12-31 | 2020-12-21 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Анти-pcsk9 антитело, его антигенсвязывающий фрагмент и их медицинское применение |
WO2017118307A1 (zh) | 2016-01-05 | 2017-07-13 | 江苏恒瑞医药股份有限公司 | Pcsk9抗体、其抗原结合片段及其医药用途 |
EP3515949A4 (en) * | 2016-09-20 | 2020-10-28 | Wuxi Biologics Ireland Limited. | NEW ANTI-PCSK9 ANTIBODIES |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
JOP20190112A1 (ar) | 2016-11-14 | 2019-05-14 | Amgen Inc | علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي |
CN108424457B (zh) * | 2017-02-13 | 2021-06-01 | 成都金洛克锶生物技术有限公司 | 针对pcsk9抗体与检测试剂盒的制备及其用途 |
JP7050807B2 (ja) | 2017-04-13 | 2022-04-08 | カディラ ヘルスケア リミティド | 新規ペプチドベースのpcsk9ワクチン |
CN113574055A (zh) | 2019-01-18 | 2021-10-29 | 阿斯利康(瑞典)有限公司 | Pcsk9抑制剂及其使用方法 |
WO2020236670A1 (en) | 2019-05-17 | 2020-11-26 | Regeneron Pharmaceuticals, Inc. | Genome-based methods for reducing cardiovascular risk |
CN114369164A (zh) * | 2020-10-15 | 2022-04-19 | 苏州君盟生物医药科技有限公司 | 抗pcsk9单克隆抗体的生产工艺 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2388617A1 (en) | 1999-10-22 | 2001-05-03 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules derived from rat brain and programmed cell death models |
AU2001280471A1 (en) | 2000-08-11 | 2002-02-25 | Eli Lilly And Company | Novel secreted proteins and their uses |
US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
CA2667989A1 (en) | 2006-11-07 | 2008-11-06 | Merck & Co., Inc. | Antagonists of pcsk9 |
US20100136028A1 (en) | 2006-11-07 | 2010-06-03 | Sparrow Carl P | Antagonists of pcsk9 |
EP2083860A4 (en) | 2006-11-07 | 2010-05-26 | Merck Sharp & Dohme | PCSK9 ANTAGONISTS |
WO2008057457A2 (en) | 2006-11-07 | 2008-05-15 | Merck & Co., Inc. | Antagonists of pcsk9 |
TW200906439A (en) | 2007-04-13 | 2009-02-16 | Novartis Ag | Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (PCSK9) |
JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
SG188814A1 (en) * | 2007-10-26 | 2013-04-30 | Merck Sharp & Dohme | Anti-pcsk9 and methods for treating lipid and cholesterol disorders |
AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
MX2010011499A (es) | 2008-04-23 | 2010-11-12 | Amgen Inc | Variantes de proproteina neutralizante de convertasa subtilisina kexina de tipo 9 (pcsk9) y sus usos. |
TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9拮抗劑類 |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
CN102596249A (zh) | 2009-10-30 | 2012-07-18 | 默沙东公司 | Ax1和ax189 pcsk9拮抗剂和变体 |
AR079336A1 (es) * | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
AU2011225716A1 (en) | 2010-03-11 | 2012-09-27 | Pfizer Inc. | Antibodies with pH dependent antigen binding |
-
2012
- 2012-08-29 AR ARP120103190A patent/AR087715A1/es unknown
- 2012-08-31 TW TW101131954A patent/TWI586687B/zh not_active IP Right Cessation
- 2012-09-12 US US13/611,196 patent/US8530414B2/en active Active
- 2012-09-12 BR BR112014005799A patent/BR112014005799A2/pt active Search and Examination
- 2012-09-12 CA CA2845706A patent/CA2845706C/en not_active Expired - Fee Related
- 2012-09-12 SG SG2014014187A patent/SG2014014187A/en unknown
- 2012-09-12 PE PE2014000352A patent/PE20141147A1/es not_active Application Discontinuation
- 2012-09-12 AP AP2014007499A patent/AP2014007499A0/xx unknown
- 2012-09-12 CN CN201280044580.3A patent/CN103781802B/zh active Active
- 2012-09-12 KR KR1020147006577A patent/KR101607783B1/ko not_active IP Right Cessation
- 2012-09-12 MX MX2014003175A patent/MX347475B/es active IP Right Grant
- 2012-09-12 AU AU2012308786A patent/AU2012308786B2/en not_active Ceased
- 2012-09-12 JP JP2014530744A patent/JP6013487B2/ja active Active
- 2012-09-12 EA EA201490470A patent/EA024430B1/ru not_active IP Right Cessation
- 2012-09-12 WO PCT/US2012/054737 patent/WO2013039958A1/en active Application Filing
- 2012-09-12 MY MYPI2014700618A patent/MY168961A/en unknown
- 2012-09-12 EP EP12761863.5A patent/EP2756003A1/en not_active Withdrawn
- 2012-09-12 UA UAA201401793A patent/UA114604C2/uk unknown
-
2014
- 2014-02-19 ZA ZA2014/01267A patent/ZA201401267B/en unknown
- 2014-02-24 CR CR20140087A patent/CR20140087A/es unknown
- 2014-02-26 DO DO2014000041A patent/DOP2014000041A/es unknown
- 2014-03-03 IL IL231282A patent/IL231282A0/en unknown
- 2014-03-06 TN TNP2014000094A patent/TN2014000094A1/en unknown
- 2014-03-11 MA MA36818A patent/MA35433B1/fr unknown
- 2014-03-12 CL CL2014000590A patent/CL2014000590A1/es unknown
- 2014-03-13 GT GT201400049A patent/GT201400049A/es unknown
- 2014-03-13 EC ECSP14013242 patent/ECSP14013242A/es unknown
- 2014-03-14 CO CO14055604A patent/CO6910164A2/es active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11904017B2 (en) | 2015-08-18 | 2024-02-20 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2014000590A1 (es) | Anticuerpo o fragmento de union a antigeno del mismo que se une a pcsk9 humana; composicion farmaceutica que lo comprende; y su uso para tratar hiperlipidemia o hipercolesterolemia. | |
CL2014002750A1 (es) | Anticuerpo aislado o fragmento que se enlaza a un estado inactiva de un receptor her; composición farmacéutica que lo comprende; uso del anticuerpo para tratar cancer | |
CL2013000843A1 (es) | Anticuerpo aislado o fragmento de union a antigeno del mismo que se une especificamente a cd48 humano y bloquea la interaccion entre cd48 humano y un receptor de cd48; composicion farmaceutica que lo comprende; y su uso. | |
CL2013000390A1 (es) | Anticuerpo monoclonal que se une al peptido beta amiloide n3pglu o fragmento de union a antigeno del mismo; composicion farmaceutica que lo comprende; y su uso para tratar la enfermedad de alzheimer. | |
GT201700102A (es) | Conjugados de anticuerpo-fármaco | |
CL2011002482A1 (es) | Anticuerpo biespecificos que se une especificamente a las proteinas erbb-3 humana y c-met humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar cancer | |
CL2012001304A1 (es) | Anticuerpo o fragmento de enlace a antígeno del mismo que se une al péptido humano c5a del sistema del complemento; composición farmacéutica que lo comprende; y su uso para el tratamiento de enfermedades inflamatorias agudas. | |
CL2014000758A1 (es) | Anticuerpo aislado o fragmento del mismo que se une especificamente a erbb3; composicion farmaceutica que lo comprende; y su uso para inhibir el crecimiento tumoral. | |
CL2013002298A1 (es) | Uso de una proteina de union con un dominio variable dual de inmunoglobulina (dvd-ig) que se une a il-1 alfa e il-1 beta para preparar un medicamento util para el tratamiento de la osteoartritis | |
BR112013013781A2 (pt) | anticorpos humanizados para liv-1 e uso dos mesmos para tratar câncer | |
CR20140585A (es) | Proteinas de union a antigeno st2 | |
CL2013003043A1 (es) | Anticuerpos de un único dominio variable dab que se unen a cd40 humano; ácido nucleico que codifica dicho anticuerpo; vector y célula huésped que lo comprenden; composición farmacéutica; uso de dichos anticuerpos para tratar enfermedad inmune. | |
CL2015000028A1 (es) | Inmunoconjugado que comprende un anticuerpo anti-cd79b unido a un agente citotóxico derivado de nemorrubicina; formulación farmacéutica que lo comprende; y uso para tratar cáncer cd79b positivo. | |
CL2013002811A1 (es) | Anticuerpo monoclonal aislado que se une a un epitopo del inhibidor de la ruta del factor tisular humano; molecula de acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar deficiencias o defectos geneticos o adquiridos en la coagulacion. | |
CL2011002304A1 (es) | Anticuerpo multiespecifico que comprende un dominio de union al antigeno que se une a egfr y a her3; acido nucleico que lo codifica; celula huesped; metodo de produccion; inmunoconjugado; formulacion farmaceutica que comprende el anticuerpo; y su uso para tratar el cancer. | |
CL2011002306A1 (es) | Anticuerpo o un fragmento de union a antigeno del mismo que se une especificamente a la integrina heterodimero alfa4beta7; y composicion que lo comprende. | |
CL2013000369A1 (es) | Anticuerpo que se une especificamente a la proteina de activacion fibroblastica (fap); polinucleotido que lo codifica; vector; celula huesped; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar cancer. | |
BR112015007672A2 (pt) | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso | |
CL2012002433A1 (es) | Anticuerpo aislado o fragmento inmunoreactivo del mismo que comprende un dominio variable que se une específicamente a un dominio extracelular del receptor b7-h3; ácido nucleico que lo codifica; hibridoma que lo secreta; reactivo de redireccionamiento de doble afinidad (dart) que lo comprende; composición farmacéutica que lo comprende; y su uso para tratar cáncer. | |
CL2008001742A1 (es) | Anticuerpo monoclonal que reconoce un epitope conformacional y se une a peptidos amiloides solubles polimericos y peptidos amiloides oligomericos; polinucleotido que lo codifica; composicion que lo comprende; y su uso para tratar enfermedades asociados a proteinas amiloides. | |
BR112014002608A2 (pt) | anticorpo ou seu fragmento que possui reatividade imunológica com um polipeptídeo caprin-1, composição farmacêutica e combinação farmacêutica de tratamento e/ou prevenção de câncer, dna e método de tratamento e/ou prevenção de câncer | |
BR112014008382A2 (pt) | anticorpo especificamente ligando a epítope no domínio sema do c-met | |
CR20120105A (es) | Proteínas terapéuticas de unión a dll4 | |
BR112015003757A2 (pt) | anticorpos e vacinas para uso no tratamento de cânceres de ror1 e inibição de metástase | |
BR112015022123A8 (pt) | Anticorpos, fragmentos de ligação ao antígeno dos mesmos que se ligam especificamente à hepcidina ou um peptídeo de hepcidina, uso, meio contentor e kit |